

IFW



PATENT
Attorney Docket No. VACCINE-07083

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: David R. Milich *et al.* Group No.: 1645
Serial No.: 10/630,070 Examiner:
Filed: 07/30/2003
Entitled: Rodent Hepatitis B Virus Core Proteins As Vaccine
Platforms And Methods Of Use Thereof

INFORMATION DISCLOSURE STATEMENT TRANSMITTAL

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8(a)(1)(i)(A)	
<p>I hereby certify that this correspondence (along with any referred to as being attached or enclosed) is, on the date shown below, being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.</p>	
Dated: <u>September 1, 2004</u>	By:  Cliff Cannon-Cm

Sir or Madam:

Enclosed please find an Information Disclosure Statement and Form PTO-1449, including copies of the references contained thereon, for filing in the U.S. Patent and Trademark Office.

The Commissioner is hereby authorized to charge any additional fee or credit overpayment to our Deposit Account No. 08-1290. An originally executed duplicate of this transmittal is enclosed for this purpose.

Dated: September 1, 2004

Malattandar

Maha A. Hamdan
Registration No. 43,655
MEDLEN & CARROLL, LLP
101 Howard Street, Suite 350
San Francisco, California 94105
415/904-6500



PATENT
Attorney Docket No. **VACCINE-07083**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: David R. Milich *et al.*

Serial No.: 10/630,070

Group No.: 1645

Filed: 07/30/2003

Examiner:

Entitled:
**Rodent Hepatitis B Virus Core Proteins As
Vaccine Platforms And Methods Of Use
Thereof**

**SECOND SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CERTIFICATE OF MAILING UNDER 37 CFR § 1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on 9-1-04.

By: CCa
Cliff Cannon-Cin

Sir or Madam:

The citation listed below, copy attached, may be material to the examination of the above-identified application, and is therefore submitted in compliance with the duty of disclosure defined in 37 C.F.R. §§ 1.56 and 1.97. The Examiner is requested to make this citation of official record in this application:

- Chang *et al.*, "Phenotypic Mixing between Different Hepadnavirus Nucleocapsid Proteins Reveals C Protein Dimerization To Be *cis* Preferential," (1994) J. Virol. 5225-5231.

This Information Disclosure Statement under 37 C.F.R. §§ 1.56 and 1.97 is not to be construed as a representation that a search has been made, that additional information material

PATENT
Attorney Docket No. **VACCINE-07083**

to the examination of this application does not exist, or that any one or more of these citations constitutes prior art.

Dated: September 1, 2004

Maha Hamdan

Maha A. Hamdan
Registration No. 43,655

MEDLEN & CARROLL, LLP
101 Howard Street, Suite 350
San Francisco, California 94105
415/904-6500

FORM PTO-144 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No.: VACCINE-07083	Serial No.: 10/630,070
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>SEARCHED, SERIALIZED, INDEXED Several Sheets If Necessary</small>		Applicant: David R. Milich <i>et al.</i>		
(37 CFR § 1.98(b))		Filing Date: 07/30/2003	Group Art Unit: 1645	
OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)				
1	Chang <i>et al.</i> , "Phenotypic Mixing between Different Hepadnavirus Nucleocapsid Proteins Reveals C Protein Dimerization To Be <i>cis</i> Preferential," (1994) J. Virol. 5225-5231			
Examiner:		Date Considered:		
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				